1-15 of 15
Kris Vaddi, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Friederike Pastore, MD, Neha Bhagwat, PhDBS, Aishwarya Krishnan, Alessandro Pastore, Bing Li, MD, Robert L Bowman, PhD, Wenbin Xiao, MD PhD, Aaron D Viny, MDMS, Abdul Karzai, Anouar Zouak, Young C Park, Keith Cordner, Stephanie Braunstein, Alexander Grego, Jaanvi Mehta, Benjamin H Durham, MD, Richard P. Koche, PhD, Jesper Maag, Peggy Scherle, PhD, Kris Vaddi, PhD, Ross L. Levine, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 473.
https://doi.org/10.1182/blood-2019-127122
Published: 2019
Journal Articles

PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma

Fiona Brown, BS, Yang Zhang, PhD, Claire Hinterschied, Alexander Prouty, BS, Shelby Sloan, BS, JoBeth Helmig-Mason, Msc, Ji Hyun Chung, PhD, Kris Vaddi, PhD, Selina Chen-Kiang, PhD, Maurizio Di Liberto, PhD, Lapo Alinari, MD PhD, Peggy Scherle, PhD, Rosa Lapalombella, PhD, Jihye Paik, PhD, Robert A Baiocchi, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 302.
https://doi.org/10.1182/blood-2019-130797
Published: 2019
Journal Articles

Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma

Shelby Sloan, BS, Fiona Brown, BS, JI Hyun Chung, PhD, Alexander Prouty, BS, Esther Wheeler, BS, Bonnie K Harrington, DVM, PhD, Eric Brooks, BS, Ayse S Yilmaz, MS, Hatice G Ozer, PhD, John C. Byrd, MD, Selina Chen-Kiang, PhD, Maurizio Di Liberto, PhD, Rosa Lapalombella, PhD, Kris Vaddi, PhD, Peggy Scherle, PhD, Youssef Youssef, MD, Robert A Baiocchi, MD PhD, Lapo Alinari, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4065.
https://doi.org/10.1182/blood-2019-128998
Published: 2019
Journal Articles

PRMT5 Is a Key Epigenetic Regulator That Promotes Transcriptional Activation in Mantle Cell Lymphoma By Regulating the Lysine Methyltransferase SETD7 and MLL1 Activity

JI Hyun Chung, PhD, Shelby Sloan, BS, Peggy Scherle, PhD, Kris Vaddi, PhD, Said Sif, PhD, Rosa Lapalombella, PhD, Robert A Baiocchi, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2777.
https://doi.org/10.1182/blood-2019-131020
Published: 2019
Journal Articles

PRMT5 Is Upregulated in Activated T Cells and Is a Novel Therapeutic Target for Acute Gvhd

Parvathi Ranganathan, PhD, Katiri Snyder, Nina Zizter, Hannah K. Choe, MD, Robert A Baiocchi, MD PhD, Kris Vaddi, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2034.
https://doi.org/10.1182/blood-2018-99-114835
Published: 2018
Journal Articles

Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I

Srdan Verstovsek, MD, PhD, Ruben A. Mesa, MD, Jason Gotlib, MD, MS, Richard S. Levy, MD, Vikas Gupta, MD, FRCP, FRCPath, John F. Dipersio, MD, PhD, John V. Catalano, MD, Michael W. Deininger, MD, PhD, Carole B. Miller, MD, Richard T. Silver, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Murat O. Arcasoy, MD, Elizabeth Hexner, MD, Roger M. Lyons, MD, Ronald Paquette, MD, Azra Raza, MD, Kris Vaddi, PhD, William Sun, PhD, Wei Peng, PhD, Victor A. Sandor, MD, CM, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2013) 122 (21): 396.
https://doi.org/10.1182/blood.V122.21.396.396
Published: 2013
Journal Articles

Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I

Srdan Verstovsek, MD, PhD, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, MD, Vikas Gupta, MD, FRCP, FRCPath, John F. DiPersio, MD, PhD, John V. Catalano, MD, Michael W.N. Deininger, MD, PhD, Carole B. Miller, MD, Richard T. Silver, MD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Murat O. Arcasoy, MD, Elizabeth O. Hexner, MD, Roger M. Lyons, MD, Ronald Paquette, MD, PhD, Azra Raza, MD, Kris Vaddi, PhD, Susan Erickson-Viitanen, PhD, William Sun, PhD, Victor A. Sandor, MD, CM, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2012) 120 (21): 800.
https://doi.org/10.1182/blood.V120.21.800.800
Published: 2012
Journal Articles

Treatment with Ruxolitinib (INCB018424) Induced Changes of Microrna Expression in Granulocytes of Patients with Polycythemia Vera and Essential Thrombocythemia,

Paola Guglielmelli, MD, PhD, Lisa Pieri, MD, Enrico Tagliarico, MD, Roberta Zini, BiSci, Ruggiero Norfo, PhD, Alberto Bosi, Kris Vaddi, PhD, DVM, Timothy Burn, PhD, Nancy Contel, Srdan Verstovsek, MD, PhD, Rossella Manfredini, BiSci, PhD, Alessandro M. Vannucchi, MD
Journal: Blood
Blood (2011) 118 (21): 3852.
https://doi.org/10.1182/blood.V118.21.3852.3852
Published: 2011
Journal Articles

Clinical Burden and Progression of Myelofibrosis in a Controlled Study Population of Placebo-Treated Patients (COMFORT-I)

Srdan Verstovsek, MD, PhD, Ruben A. Mesa, MD, Jason Gotlib, MD, MS, Richard S. Levy, MD, Vikas Gupta, MD, FRCP, FRCPath, John F. DiPersio, MD, PhD, John Catalano, MD, Michael W. Deininger, Carole B. Miller, MD, Richard T. Silver, MD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Murat O. Arcasoy, MD, Elizabeth Hexner, MD, Roger M. Lyons, MD, Ronald Paquette, MD, PhD, Azra Raza, MD, Kris Vaddi, PhD, Sue Erickson-Viitanen, PhD, William Sun, PhD, Victor A. Sandor, MD, CM, Hagop M. Kantarjian
Journal: Blood
Blood (2011) 118 (21): 5146.
https://doi.org/10.1182/blood.V118.21.5146.5146
Published: 2011
Journal Articles

Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I

Srdan Verstovsek, MD, PhD, Ruben A. Mesa, MD, Jason Gotlib, MD, MS, Richard S. Levy, MD, Vikas Gupta, MD, FRCP, FRCPath, John F. DiPersio, MD, PhD, John Catalano, MD, Michael W. Deininger, Carole B. Miller, MD, Richard T. Silver, MD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Murat O. Arcasoy, MD, Elizabeth Hexner, MD, Roger M. Lyons, MD, Ronald Paquette, MD, PhD, Azra Raza, MD, Kris Vaddi, PhD, Sue Erickson-Viitanen, PhD, William Sun, PhD, Victor A. Sandor, MD, CM, Hagop M. Kantarjian
Journal: Blood
Blood (2011) 118 (21): 278.
https://doi.org/10.1182/blood.V118.21.278.278
Published: 2011
Journal Articles

Characterization of JAK2 V617F Allele Burden in Advanced Myelofibrosis (MF) Patients: No Change in V617F:WT JAK2 Ratio in Patients with High Allele Burdens despite Profound Clinical Improvement Following Treatment with the JAK Inhibitor, INCB018424

Srdan Verstovsek, MD, PhD, Hagop M. Kantarjian, MD, Animesh D. Pardanani, MBBS, PhD, Timothy Burn, PhD, Kris Vaddi, PhD, DVM, John Redman, MD, Edward C Bradley, MD, Richard Levy, MD, Steven Friedman, MD, Gregory Hollis, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2008) 112 (11): 2802.
https://doi.org/10.1182/blood.V112.11.2802.2802
Published: 2008
Journal Articles

The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).

Srdan Verstovsek, Hagop M. Kantarjian, MD, Animesh D. Pardanani, MBBS, PhD, Deborah Thomas, MD, Jorge Cortes, MD, Ruben A. Mesa, MD, FACP, William J. Hogan, MBChB, John R. Redman, MD, Sue Erickson-Viitanen, Richard Levy, MD, Kris Vaddi, PhD, DVM, Edward Bradley, MD, Jordan Fridman, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2008) 112 (11): 1762.
https://doi.org/10.1182/blood.V112.11.1762.1762
Published: 2008
Journal Articles

INCB018424, an Oral, Selective JAK2 Inhibitor, Shows Significant Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).

Srdan Verstovsek, MD, PhD, Hagop Kantarjian, MD, Animesh Pardanani, MD, PhD, Deborah Thomas, MD, Jorge Cortes, MD, Ruben Mesa, MD, John Redman, MD, Carl-Michael Staschen, MD, PhD, Jordan Fridman, PhD, Kris Vaddi, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2007) 110 (11): 558.
https://doi.org/10.1182/blood.V110.11.558.558
Published: 2007
Journal Articles

Discovery and Preclinical Characterization of INCB018424, a Selective JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders.

Jordan Fridman, PhD, Roberto Nussenzveig, PhD, Phillip Liu, PhD, James Rodgers, PhD, Timothy Burn, PhD, Patrick Haley, DVM, Peggy Scherle, PhD, Robert Newton, PhD, Gregory Hollis, PhD, Steven Friedman, MD, Srdan Verstovsek, MD, PhD, Kris Vaddi, PhD
Journal: Blood
Blood (2007) 110 (11): 3538.
https://doi.org/10.1182/blood.V110.11.3538.3538
Published: 2007
Journal Articles

The JAK Inhibitor INCB20 Induces Antiproliferative and Apoptotic Effects in Human Myeloma Cells In Vitro and In Vivo .

Renate Burger, PhD, Steven Legouill, MD, Yu-Tzu Tai, PhD, Reshma Shringarpure, PhD, Klaus Podar, MD, PhD, Laurence Catley, MD, Pierfrancesco Tassone, MD, Paola Neri, MD, Teru Hideshima, MD, Dharminder Chauhan, PhD, Eian Caulder, BS, Kris Vaddi, PhD, Claire L. Neilan, PhD, Martin Gramatzki, MD, Jordan S. Fridman, PhD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2005) 106 (11): 3357.
https://doi.org/10.1182/blood.V106.11.3357.3357
Published: 2005